The impact of chronic kidney disease in diabetic COVID-19 patients

H.Chaabouni, I.Bougharriou, K.Mnif, M.Maazoun, T.Ben Jemaa, K.Rekik, F.Smaoui, M.Koubaa, C.Marrakchi, B.Hammami, M.Ben Jemaa

Infectious Diseases Department, Hedi Chaker University Hospital, University of Sfax, Tunisia

BACKGROUND:

- People who are already suffering from pre-existing medical conditions are at a higher risk to develop a severe form of COVID-19 infection.
- We aimed to describe the impact of chronic kidney disease (CKD) in diabetic COVID-19 patients.

PATIENTS AND METHODS:

- A retrospective study, including diabetic COVID-19 patients.
- Hospitalized in an infectious diseases department
- November 2020 -February 2021.
- The population was divided into:
 - \checkmark **G1** (with CKD).
 - ✓ G2 (without CKD).

RESULTS:

- In total, 153 patients were collected.
- The mean age : 68±11 years old.
- The prevalence of CKD in the population (Figure 1)




Figure1: The prevalence of CKD in diabetic COVID-19 patients

The male to female ratio: 2.06 (p>0.05).

The table I shows the comparison between G1 and G2.

Table I: The impact of chronic kidney disease in diabetic COVID-19 patients

Parameter	G1 (with CKD) 56patients	G2 (without CKD) 97 patients	р
Age (years)	70	66	0,03
Hypertension	77%	51%	0,01
Time from symptom onset to healthcare consult (days)	7	6	0,2
Dyspnea	80%	84%	0,1
Diabetes disorder	92%	82%	<0.01
Dyskalemia	21%	12%	<0.01
Severe radiologic forms	57%	62%	0.2
Death	14%	18%	0.2

CONCLUSION:

- Diabetic patients with CKD are older and with more cardiovascular comorbidities. They are also exposed to ionic and diabetes disorders.
- But multicentric studies should be realized to evaluate the effect of CKD on the COVID-19 outcomes.

19th Annual WORLD CONGRESS INSULIN RESISTANCE DIABETES & CARDIOVASCULAR DISEASE

CME Conference | December 2-4, 2021 Hilton Universal Hotel, Los Angeles, CA